phase readout
saveNCT05388669: A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
ACTIVE_NOT_RECRUITINGupdated 10d ago
community read0 votes
Sponsor: Janssen Research & Development, LLC. Phase: PHASE3. Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that